Barclays has begun analyzing Repligen Corporation (RGEN, Financial), awarding it an Overweight rating and setting a price target of $150. The financial institution appreciates Repligen's robust position within the bioprocessing sector, which it considers the most appealing subsector due to its resilience against significant macroeconomic challenges affecting the industry. Repligen’s strong focus on clinical applications enhances its attractiveness as an investment, according to Barclays' assessment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Repligen Corp (RGEN, Financial) is $183.60 with a high estimate of $220.00 and a low estimate of $140.00. The average target implies an upside of 52.86% from the current price of $120.11. More detailed estimate data can be found on the Repligen Corp (RGEN) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Repligen Corp's (RGEN, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Repligen Corp (RGEN, Financial) in one year is $176.46, suggesting a upside of 46.92% from the current price of $120.11. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Repligen Corp (RGEN) Summary page.
RGEN Key Business Developments
Release Date: April 29, 2025
- Revenue: $169 million for Q1 2025, a 10% increase year-over-year.
- Organic Revenue Growth: 11% overall, 14% organic non-COVID growth.
- Adjusted Gross Margin: 53.7%, up nearly 450 basis points from last year.
- Adjusted Income from Operations: $23 million, up 72% year-over-year.
- Adjusted Operating Margin: 13.8%, up 490 basis points from Q1 2024.
- Adjusted EBITDA Margin: 19.3% for Q1 2025.
- Adjusted Net Income: $22 million, a 29% increase from Q1 2024.
- Adjusted Diluted EPS: $0.39, up 29% from $0.30 in Q1 2024.
- Cash Position: $697 million at the end of Q1 2025.
- Biopharma Revenue Growth: Over 20% year-on-year, excluding COVID.
- Consumable Revenue Growth: Greater than 20% year-on-year, excluding Proteins.
- Process Analytics Growth: 20% growth, including $1 million from the 908 acquisition.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Repligen Corp (RGEN, Financial) reported a strong start to 2025 with 11% organic revenue growth in Q1, and 14% organic non-COVID growth.
- The company experienced high growth in its Proteins franchise, outperforming expectations, and Chromatography and Analytics both grew double digits.
- Orders were up high teens year-on-year with all franchises growing double digits, indicating strong demand across the portfolio.
- Repligen Corp (RGEN) made strategic progress with the acquisition of 908 Devices' bioprocessing portfolio, enhancing its position in new modalities and process analytics technology.
- The company maintained a strong cash position of $697 million at the end of Q1 2025, providing financial flexibility for future investments and acquisitions.
Negative Points
- Repligen Corp (RGEN) faced challenges in the capital equipment segment, with revenues declining year-on-year due to timing issues.
- China's market performance was weak, representing only 2% of Q1 revenues and orders, highlighting regional challenges.
- The small biotech segment showed weakness, with sales to emerging markets declining by high single digits.
- The company is exposed to potential tariff impacts, particularly in Europe, which could affect revenue and margins if retaliatory duties are imposed.
- Biotech funding decreased significantly in Q1 2025, which could impact the future health of the ecosystem and Repligen Corp (RGEN)'s growth prospects.
